XL647

DRUG5 trials

Sponsors

Kadmon Corporation, LLC, Exelixis

Conditions

Breast CancerCancerCarcinoma, Non-Small-Cell LungNon-small-cell Lung Cancer

Phase 1

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

CompletedNCT00086528

Kadmon Corporation, LLCCancer

Start: 2004-06-30End: 2007-11-30Updated: 2022-05-13

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

CompletedNCT00336765

Kadmon Corporation, LLCCancer

Start: 2006-07-31End: 2010-09-30Updated: 2022-05-13

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

WithdrawnNCT00704392

ExelixisBreast Cancer, Cancer, Non-small-cell Lung Cancer

Start: 2008-06-30End: 2009-12-31Updated: 2015-08-20

Phase 2

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

CompletedNCT00364780

Kadmon Corporation, LLCNon-small-cell Lung Cancer

Start: 2006-07-31End: 2010-08-31Updated: 2022-05-13

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

CompletedNCT00522145

Kadmon Corporation, LLCCarcinoma, Non-Small-Cell Lung

Start: 2007-05-31End: 2010-02-28Updated: 2022-05-13